Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease
Article first published online: 7 APR 2009
© 2009 Johnson and Johnson Pharmaceutical Research and Development, LLC. Journal compilation © 2009 Blackwell Publishing Ltd
Clinical & Experimental Allergy
Volume 39, Issue 8, pages 1179–1186, August 2009
How to Cite
Belkowski, S. M., Boot, J. D., Mascelli, M. A., Diamant, Z., De Garavilla, L., Hertzog, B., Polkovitch, D., Towers, M., Batheja, A. and D'Andrea, M. R. (2009), Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease. Clinical & Experimental Allergy, 39: 1179–1186. doi: 10.1111/j.1365-2222.2009.03247.x
- Issue published online: 9 JUL 2009
- Article first published online: 7 APR 2009
- Submitted 13 October 2008; revised 20 January 2009; accepted 18 February 2009
- mast cell;
Background Secretory leucocyte protease inhibitor (SLPI), which is present in many physiological fluids including saliva, sputum and nasal discharge, is the most effective inhibitor of chymase. Previously, we demonstrated that chymase is able to cleave SLPI and that the cleaved portion, cSLPI, is a biomarker of chymase activity.
Objective We investigated the potential of cSLPI as a biomarker of chymase activity in subjects with allergic rhinitis (AR) and asthmatic airway disease.
Methods Baseline sputum samples were collected from atopic asthmatics and healthy controls (HC). Nasal lavages (NAL) were performed in subjects with AR both at baseline and following a nasal challenge with allergen or placebo. Levels of cSLPI and chymase were determined by Western analysis, and tryptase and α-2 macroglobulin were measured by immunoassay.
Results As compared with HC, asthmatics showed a significant increase in baseline cSLPI/total SLPI ratios and an increase in chymase levels. There was a high correlation of cSLPI/SLPI ratios to chymase levels in normal individuals and untreated asthmatics. In the NAL of patients with AR, as compared with placebo, allergen challenge increased inflammatory biomarkers, including cSLPI/SLPI ratios, chymase levels, tryptase levels and α2-macroglobulin levels. Correlations were observed between cSLPI/SLPI ratios and chymase levels and cSLPI/SLPI ratios and α2-macroglobulin levels; no correlation was seen between cSLPI/SLPI ratios and tryptase levels.
Conclusion Our data indicate that cSLPI reflects chymase activity in AR and asthma. Hence, cSLPI may serve as a biomarker for disease activity and for monitoring the efficacy of novel anti-inflammatory treatments in chymase-mediated diseases.